INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 47 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $10,031,000 | -17.2% | 12,400,000 | -22.5% | 0.01% | -26.3% |
| Q2 2020 | $12,120,000 | +23.8% | 16,000,000 | +34.9% | 0.02% | +5.6% |
| Q1 2020 | $9,788,000 | +41.8% | 11,864,000 | +73.8% | 0.02% | +80.0% |
| Q4 2019 | $6,901,000 | -45.0% | 6,828,000 | -51.2% | 0.01% | -50.0% |
| Q2 2019 | $12,552,000 | +9.7% | 14,000,000 | +21.7% | 0.02% | +5.3% |
| Q1 2019 | $11,437,000 | +194.2% | 11,500,000 | +130.0% | 0.02% | +171.4% |
| Q3 2017 | $3,887,000 | -68.2% | 5,000,000 | -60.0% | 0.01% | -69.6% |
| Q2 2017 | $12,218,000 | +30.4% | 12,500,000 | +25.0% | 0.02% | +27.8% |
| Q1 2017 | $9,368,000 | -9.3% | 10,000,000 | -13.2% | 0.02% | -14.3% |
| Q4 2016 | $10,329,000 | -44.3% | 11,525,000 | -30.2% | 0.02% | -43.2% |
| Q3 2016 | $18,531,000 | – | 16,500,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Worth Venture Partners, LLC | 5,324,000 | $4,995,000 | 3.78% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 57,791,000 | $53,020,000 | 2.12% |
| DLD Asset Management, LP | 32,500,000 | $30,048,000 | 2.06% |
| Castle Creek Arbitrage, LLC | 4,504,000 | $4,161,000 | 1.43% |
| TENOR CAPITAL MANAGEMENT Co., L.P. | 10,000,000 | $9,372,000 | 0.62% |
| Graham Capital Management, L.P. | 14,636,000 | $13,509,000 | 0.60% |
| OAKTREE CAPITAL MANAGEMENT LP | 64,452,000 | $59,704,000 | 0.54% |
| Context Capital Management, LLC | 1,000,000 | $926,000 | 0.52% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 23,118,000 | $21,341,000 | 0.52% |
| WOLVERINE ASSET MANAGEMENT LLC | 18,583,000 | $17,322,000 | 0.21% |